LifeStance Health Group (NASDAQ:LFST) Upgraded to “Buy” at Wall Street Zen

LifeStance Health Group (NASDAQ:LFST) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Sunday.

A number of other brokerages also recently issued reports on LFST. BMO Capital Markets initiated coverage on shares of LifeStance Health Group in a report on Thursday, November 13th. They issued an “outperform” rating and a $8.00 price target on the stock. Barclays assumed coverage on shares of LifeStance Health Group in a report on Tuesday, December 9th. They set an “overweight” rating and a $8.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of LifeStance Health Group in a report on Monday, December 29th. UBS Group boosted their price target on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Finally, BTIG Research increased their price objective on LifeStance Health Group from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $9.00.

LifeStance Health Group Price Performance

Shares of NASDAQ LFST opened at $6.84 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.58 and a current ratio of 1.58. LifeStance Health Group has a fifty-two week low of $3.74 and a fifty-two week high of $8.30. The stock has a market cap of $2.66 billion, a PE ratio of -228.00 and a beta of 1.12. The stock has a fifty day moving average of $7.01 and a 200-day moving average of $5.90.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. The business had revenue of $363.81 million for the quarter, compared to analysts’ expectations of $355.06 million. LifeStance Health Group had a negative return on equity of 0.62% and a negative net margin of 0.67%.The firm’s quarterly revenue was up 16.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.02) EPS. Equities research analysts anticipate that LifeStance Health Group will post -0.18 earnings per share for the current year.

Insider Transactions at LifeStance Health Group

In other news, insider Ann Varanakis sold 50,000 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total transaction of $345,000.00. Following the sale, the insider owned 315,610 shares in the company, valued at approximately $2,177,709. This trade represents a 13.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Robert Bessler sold 119,942 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $7.04, for a total transaction of $844,391.68. Following the completion of the transaction, the director owned 1,318,983 shares of the company’s stock, valued at $9,285,640.32. This trade represents a 8.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 327,326 shares of company stock valued at $2,259,317 in the last quarter. Insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On LifeStance Health Group

Several institutional investors have recently modified their holdings of LFST. Vanguard Group Inc. lifted its position in LifeStance Health Group by 21.1% in the 4th quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock worth $124,608,000 after buying an additional 3,086,506 shares during the last quarter. Dimensional Fund Advisors LP grew its position in LifeStance Health Group by 27.2% during the third quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company’s stock valued at $45,998,000 after acquiring an additional 1,790,694 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of LifeStance Health Group by 62.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock worth $26,363,000 after acquiring an additional 1,839,465 shares in the last quarter. Barclays PLC raised its stake in shares of LifeStance Health Group by 74.7% during the third quarter. Barclays PLC now owns 3,508,552 shares of the company’s stock worth $19,297,000 after acquiring an additional 1,499,687 shares in the last quarter. Finally, AustralianSuper Pty Ltd bought a new stake in shares of LifeStance Health Group in the 3rd quarter worth approximately $17,056,000. 85.50% of the stock is currently owned by institutional investors.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.